Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2007

Pfizer to Buy BioRexis

  • Pfizer reports that it plans to acquire BioRexis Pharmaceutical, a privately-held biopharmaceutical company with a number of diabetes candidates and a novel technology platform for developing new protein drug candidates.

    "Through this acquisition, we are investing in a company with an exciting new technology and potential new product candidates in diabetes," says Edmund P. Harrigan, M.D., senior vp, worldwide licensing and new business development for Pfizer.

    BioRexis is developing long-acting GLP-1 receptor agonists for the treatment of type 2 diabetes. It also developed protein-engineering technologies based on human transferrin that provides therapeutic agents with longer duration of action than synthetic peptides, according to Pfizer. In addition to reducing dosing frequency, these technologies have the potential to improve patient tolerability as compared to other evolving protein therapeutic technologies, Pfizer adds.

    The acquisition is expected to close during the first or second quarter of this year.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »